Effect of PF-02341066 and radiation on non-small cell lung cancer cells

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1094-1100

  Tumati, Vasu ^a   Kumar, Subashri ^a   Yu, Lan ^a   Chen, Benjamin ^a,b   Choy, Hak ^a,b   Saha, Debabrata ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ALK inhibitors; Animal models; DNA double strand break repair; Non small cell lung cancer; Radiation resistance; Radio sensitization; Tumor growth delay

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; HYBRID PROTEIN; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL FRACTIONATION; CELL SURVIVAL; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MICE; MICE, NUDE; PYRAZOLES; PYRIDINES; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872793465     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2198     Document Type: Article

References (20)

1. jemal A, bray F, Center MM, Ferlay j, Ward E and Forman D: Global cancer statistics. CA Cancer j Clin 61: 69-90, 2011.
2. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 448: 561-566, 2007. (Pubitemid 47206930)
3. Kwak EL, bang Yj, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl j Med 363: 1693-1703, 2010.
4. Rodig Sj, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216-5223, 2009.
5. Choi YL, Takeuchi K, Soda M, et al: Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68: 4971-4976, 2008.
6. Soda M, Takada S, Takeuchi K, et al: A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 105: 19893-19897, 2008.
7. Yamazaki S, Vicini P, Shen Z, et al: Pharmacokinetic/pharmaco-dynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. j Pharmacol Exp Ther 340: 549-557, 2011.
8. Lin E, Li L, Guan Y, et al: Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7: 1466-1476, 2009.
9. Kodym E, Kodym R, Reis AE, Habib AA, Story MD and Saha D: The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer 66: 37-47, 2009.
10. Kong Z, Raghavan P, Xie D, et al: Epothilone b confers radiation dose enhancement in DAb2IP gene knock-down radioresistant prostate cancer cells. Int j Radiat Oncol biol Phys 78: 1210-1218, 2010.
11. Kim jC, Saha D, Cao Q and Choy H: Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 71: 213-221, 2004. (Pubitemid 38521191)
12. Ou SH: Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 5: 471-485, 2011.
13. bai RY, Ouyang T, Miething C, Morris SW, Peschel C and Duyster j: Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. blood 96: 4319-4327, 2000.
14. Chen Z, Sasaki T, Tan X, et al: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 70: 9827-9836, 2010.
15. Fan S, Ma YX, Gao M, et al: The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell biol 21: 4968-4984, 2001. (Pubitemid 32656395)
16. Christensen jG, Zou H Y, Arango ME, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6: 3314-3322, 2007.
17. De bacco F, Luraghi P, Medico E, et al: Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. j Natl Cancer Inst 103: 645-661, 2011.
18. Aebersold DM, Kollar A, beer KT, Laissue j, Greiner RH and Djonov V: Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of bcl-xL in the resistance of oropha-ryngeal cancer to ionizing radiation. Int j Cancer 96: 41-54, 2001. (Pubitemid 32147684)
19. brognard j, Clark AS, Ni Y and Dennis PA: Akt/protein kinase b is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001. (Pubitemid 32720961)
20. McDermott U, Iafrate Aj, Gray NS, et al: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68: 3389-3395, 2008.